Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics is a strong investment opportunity due to their unique focus on fibroblast-based therapies and their proprietary fibroblast spheroid technology, which has the potential to facilitate wound healing and tissue regeneration. The company has a deep intellectual property moat and a versatile platform that can be applied to multiple indications. Near-term catalysts include ongoing clinical trials for their lead candidate CYWC628 in diabetic foot ulcers, as well as progress in their burn program and expansion of their IP portfolio. However, risks include clinical and regulatory factors, partnerships, and financial challenges.

Bears say

FibroBiologics is seen as a risky investment due to its current developmental stage and the potential for failure in achieving peak commercial revenue for its product candidates. With an adjusted price target of $8 per share based on a discounted cash flow and earnings multiple analysis, it is clear that the company's current market valuation may be inflated and not reflective of its actual financial performance. The recent 1-for-20 reverse stock split may also lead to selling pressure and reduced trading liquidity, further adding to the risk and volatility of the stock. Until the company can show stable trading dynamics and demonstrate successful commercialization, a Hold rating may be more appropriate for this stock.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.